SEC Form 4 · accession 0001225208-16-033624
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick B Verguet
Officer — CVP, Europe
Period of report
May 16, 2016
Accepted (ET)
May 18, 2016 · 8:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 16, 2016 | M | 19,337 | $0.00 | A | 129,944 | D | |
| Common StockF2 | May 16, 2016 | M | 3,000 | $25.48 | A | 132,944 | D | |
| Common StockF1,F2 | May 16, 2016 | F | 992 | $102.99 | D | 131,952 | D | |
| Common StockF3,F2 | May 16, 2016 | S | 3,000 | $104.6187 | D | 128,952 | D | |
| Common StockF2 | May 17, 2016 | M | 5,000 | $25.48 | A | 133,952 | D | |
| Common StockF2 | May 17, 2016 | S | 5,000 | $105.00 | D | 128,952 | D | |
| Common StockF2 | May 18, 2016 | M | 5,000 | $25.48 | A | 133,952 | D | |
| Common StockF2 | May 18, 2016 | S | 5,000 | $99.371 | D | 128,952 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire)F2 | $25.48 | May 16, 2016 | M | 3,000 | D | May 13, 2011 | May 12, 2017 | Common Stock | 3,000 | 98,000 | D |
| Performance RightsF1,F2 | — | May 16, 2016 | M | 19,337 | D | — | Mar 31, 2016 | Common Stock | 19,337 | 0 | D |
| Employee Stock Option (Right to Acquire)F2 | $25.48 | May 17, 2016 | M | 5,000 | D | May 13, 2011 | May 12, 2017 | Common Stock | 5,000 | 93,000 | D |
| Employee Stock Option (Right to Acquire)F2 | $25.48 | May 18, 2016 | M | 5,000 | D | May 13, 2011 | May 12, 2017 | Common Stock | 5,000 | 88,000 | D |
Explanation of responses
- F1On May 14, 2013, the Reporting Person was granted a target number of shares (11,050) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2016, 175% of the target shares vested and were issued, and the actual number of shares vested are reflected on this Form.
- F2This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.
- F3This transaction was executed in multiple trades at prices ranging from $104.61 to $104.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.